Table 1.

NONMEM parameter estimates (with 95% confidence intervals) and bootstrapped estimates (median and 95% of estimates) for the final paediatric brivaracetam model using LBW-dependent CL and V (normalised to a 50-kg LBW adult), and effects of co-administration of PB, CBZ and VPA

Parameter	NONMEM estimates	Bootstrapped estimates	IIV	Shrinkage (%)
CL/F (L/h)	3.63 (3.42/3.85)	3.62 (3.42/3.86)	22.8%	6.1%
V/F (L)	47.8 (43.1/52.5)	47.6 (43.1/51.7)	16.7%	45.6%
Ka (1/h)	1.84 (0.91/2.78)	1.83 (1.26/5.27)	31.9%	73.4%
Allometric scaling CL/F	0.750 fixed
Allometric scaling V/F	1.00 fixed
CL change with PB (%)	+40.8 (+19.9/+65.2)	+39.8 (+18.3/+65.8)
CL change with CBZ (%)	+47.9 (+27.8/+71.2)	+48.2 (+26.2/+73.0)
CL change with VPA (%)	−10.1 (−18.5/−0.8)	−10.0 (−19.5/−0.8)
Residual error (CV, %)	23.4 (19.6/27.1)	23.2 (19.7/26.7)		9.2%